The International Association for the Study of Lung Cancer/X
Jan 23, 2025, 16:29
FDA approval: Zenocutuzumab for NRG1+ NSCLC – IASLC
The International Association for the Study of Lung Cancer (IASLC) shared a post on X:
“ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion.
Catch this all-new episode of Lung Cancer Considered as Stephen V Liu and Alison Schram discuss this breakthrough and what this approval means for treating NSCLC patients with an NRG1 fusion
More posts featuring IASLC.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 11:33
Feb 25, 2025, 11:24
Feb 25, 2025, 11:23
Feb 25, 2025, 11:17
Feb 25, 2025, 11:15
Feb 25, 2025, 11:11
Feb 25, 2025, 11:04
Feb 25, 2025, 11:03